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Abstract 
Review on CARTPT, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: CART 
HGNC (Hugo): CARTPT 
Location: 5q13.2 
Note 
Cocaine- and amphetamine-regulated transcript 
(CART) was discovered in 1995 by Douglass et al. 
as an mRNA that was upregulated in the rat brain in 
response to psychostimulant administration 
(Douglass et al., 1995). 
DNA/RNA 
Description 
The human CARTPT gene spans 1886 base pairs 
and includes three exons and two introns (Douglass 
and Daoud, 1996). 
Transcription 
Transcription of the 1886 base pair (bp) long 
CARTPT gene including three exons, yields a 933 
bases CARTPT mRNA, which in turn is translated  
into the 116 amino acid (aa) long prepro-CART 
peptide. The first 27 amino acid residues serve as a 
hydrophobic N-terminal signal sequence, which is 
cleaved, resulting in the 89 aa long pro-CART 
peptide (Douglass et al., 1995). Pro-CART is 
subsequently subject to processing by 
prohormone/proprotein convertases (PCs) during 
the regulated secretory pathway in the Golgi 
apparatus, immature secretory granules and finally 
mature secretory granules (Stein et al., 2006b). 
PC1/3 is primarily responsible for producing the 
intermediate peptide 10-89, whereas PC2 and to a 
lesser extent PC5/6A generate the two bioactive 
CART peptides (42-89 and 49-89) (Stein et al., 
2006a; Stein et al., 2006b).  
In addition, there are a number of smaller CART 
peptide fragments of uncertain importance (Kuhar 
and Yoho, 1999; Dylag et al., 2006; Stein et al., 
2006b). 
Protein 
Description 
Prepro-CART is a 116 aa long peptide with a 
molecular weight of 12829 Da.  
As described above, posttranslational modifications 
yield an 89 aa long pro-CART peptide (28-116) and 
eventually two bioactive CART peptides (42-89 
and 49-89). 
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Expression 
CART peptides have been found in the central, 
peripheral and enteric nervous systems, and also in 
endocrine cells in the pancreatic islets (Jensen et al., 
1999; Wierup et al., 2004; Wierup and Sundler, 
2006), the GI tract mucosa (Ekblad et al., 2003), the 
thyroid (Wierup et al., 2007), and the adrenal 
medulla (Dun et al., 2006). 
Localisation 
CART is localized to the secretory granules of 
neuroendocrine cells as demonstrated in rat 
pancreatic β-cells (Wierup et al., 2006). 
Function 
CART peptide is a brain-gut peptide, acting both as 
a neurotransmitter and as a hormone. Within the 
CNS, the spatial distribution of CART peptides 
together with various experimental studies suggest 
a role of CART peptides in regulating food intake 
and body weight (Kuhar et al., 1999; Rogge et al., 
2008) with an overall anorexigenic effect via 
largely unknown mechanisms (Hunter et al., 2004; 
Rogge et al., 2008). This is also supported by 
observations that CARTPT null mice and humans 
carrying a mutated CARTPT gene develop obesity 
and signs of type 2 diabetes (Asnicar et al., 2001; 
del Giudice et al., 2001; Guérardel et al., 2005; 
Wierup et al., 2005). In addition, there is evidence 
of CART involvement in other brain processes such 
as mechanisms of reward and stress response 
(Kuhar et al., 1999; Jaworski et al., 2006; Rogge et 
al., 2008). 
Hormonal expression of CART in pancreatic islets 
occurs mainly in somatostatin-producing δ-cells 
(Jensen et al., 1999; Wierup and Sundler, 2006), 
and the produced CART peptides participate in the 
regulation of insulin, glucagon, and somatostatin 
secretion (Wierup and Sundler, 2006; Wierup et al., 
2006). Indeed, CART is necessary for normal islet 
function, since Cart null mice have diminished 
insulin secretion and reduced glucose elimination 
(Wierup et al., 2005). Interestingly, there is recent 
evidence that CART is crucial for pancreatic islet β-
cell viability, both by reducing apoptosis and by 
increasing proliferation via several different 
pathways (Sathanoori et al., 2013). 
Within the GI tract mucosa, CART expression has 
been identified mainly in gastrin-producing G-cells 
(Ekblad et al., 2003). The physiological function of 
CART in the enteric neurons and GI endocrine cells 
remains poorly elucidated (Ekblad, 2006). 
Homology 
CART is highly conserved between species. The 
amino acid sequence is 95% identical between 
humans, rats and mice (Douglass and Daoud, 1996; 
Stein et al., 2006b). Goldfish pro-CART peptide is 
40-50% homologous to the mammalian counterpart, 
with 70-80% homology in the biologically active 
C-terminal portions of the peptide (Volkoff and 
Peter, 2001). 
Mutations 
Somatic 
A missense mutation resulting in the substitution of 
Leu with Phe at codon 34, within the NH2-terminal 
CART region, was identified in an Italian family. 
Heterozygosity for this mutation was associated 
with severe obesity within the family and was not 
found in controls. Resting metabolic rates were 
lower than expected in subjects with the mutation 
(del Giudice et al., 2001). 
A SNP within the CARTPT gene (SNP-3608T>C 
(rs7379701/rs4703647)) has been demonstrated to 
possibly contribute to the genetic risk for obesity 
(Guérardel et al., 2005). 
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Implicated in 
Neuroendocrine neoplasia (NEN) 
Note 
CART expression in neoplastic tissue was first 
demonstrated in rat pancreatic islet tumours (Jensen 
et al., 1999). CART was later found to co-localize 
with insulin in human insulin-producing pancreatic 
neuroendocrine neoplasia (NEN) (Wierup and 
Sundler, 2006). Next, Bech et al. found raised 
levels of circulating CART in patients with a wide 
range of various NENs (Bech et al., 2008). We 
recently demonstrated presence of CART in tumour 
tissue of human NENs originating in the stomach, 
ileum, rectum, pancreas, and thyroid (Landerholm 
et al., 2011). 
Disease 
CARTPT is expressed in several types of NENs 
including gastric NEN, small intestinal NEN (SI-
NEN), rectal NEN, pancreatic NEN (P-NEN) and 
medullary thyroid cancer. CART peptide is not 
detected in all tumours, and when present levels 
range from scarce to abundant (Landerholm et al., 
2011). 
Prognosis 
As CART is expressed in all examined types of 
NEN, it is a tentative diagnostic and/or prognostic 
biomarker (Landerholm et al., 2011). The only 
study to date investigating the use of circulating 
CART found that the presently used Chromogranin 
A outperforms CART as a general diagnostic NEN 
biomarker (Bech et al., 2008; Bech et al., 2013). 
However, the sensitivity of CART was better for P-
NENs than other NENs and circulating CART was 
raised in 95% of progressive P-NENs. 
There is also only one study of tumour tissue 
CART as a biomarker for NENs, demonstrating that 
increasing CART levels are associated with worse 
survival in SI-NENs (see below) (Landerholm et 
al., 2012). 
Small intestinal neuroendocrine 
tumours (SI-NETs) 
Disease 
Neuroendocrine tumours (NETs) correspond to 
grade 1 and 2 NENs, as opposed to grade 3 
neuroendocrine carcinomas (NECs) (Rindi et al., 
2007; Sobin et al., 2009). SI-NETs arise from 
enteroendocrine cells or their precursors in the 
small intestinal mucosa. At presentation, a majority 
of SI-NET patients already have metastases to 
regional mesenteric lymph nodes or to distant sites, 
in particular the liver. SI-NETs are typically slow-
growing and produce and secrete several bioactive 
substances including serotonin, tachykinins and 
growth factors. These substances cause several 
symptoms that are characteristical of SI-NETs; in 
particular marked fibrosis of the mesentery, 
diarrhoea, flushing, and tricuspid valvular lesions. 
CART peptide has been detected in varying levels 
in SI-NET primary tumours and metastases 
(Landerholm et al., 2011), but no association was 
found between tumour CART levels and the 
abovementioned symptoms (Landerholm et al., 
2012). 
Prognosis 
The only study to investigate CART expression as a 
prognostic factor in SI-NET found that increasing 
CART peptide levels in the tumour was 
independently associated with worse survival 
(Landerholm et al., 2012). 
Oncogenesis 
Addition of CART peptide in vitro caused an 
increase in viability of cell lines GLUTag (murine 
enteroendocrine cancer cell line) and HCT-116 
(human colon cancer cell line) via enhanced 
proliferation (Landerholm et al., 2012). 
Breast cancer 
Note 
CART peptide is expressed in tumour cells in some 
primary breast cancer tumours and, when present, 
also in their corresponding lymph node metastases. 
CART peptide has not been found in normal breast 
tissue (Brennan et al., 2012). 
Prognosis 
High CART was an independent poor prognostic 
factor for overall survival in lymph node negative 
breast cancer.  
CART was found to induce transcriptional activity 
of estrogen receptor-α (ERα) in a ligand-
independent manner.  
In vitro, CART protected breast cancer cells from 
tamoxifen-mediated cell death and in three breast 
cancer cohorts high CART expression was 
predictive of poor outcome in tamoxifen-treated 
patients (Brennan et al., 2012). 
References 
Douglass J, McKinzie AA, Couceyro P. PCR differential 
display identifies a rat brain mRNA that is transcriptionally 
regulated by cocaine and amphetamine. J Neurosci. 1995 
Mar;15(3 Pt 2):2471-81 
Douglass J, Daoud S. Characterization of the human 
cDNA and genomic DNA encoding CART: a cocaine- and 
amphetamine-regulated transcript. Gene. 1996 Mar 
9;169(2):241-5 
Jensen PB, Kristensen P, Clausen JT, Judge ME, Hastrup 
S, Thim L, Wulff BS, Foged C, Jensen J, Holst JJ, Madsen 
OD. The hypothalamic satiety peptide CART is expressed 
in anorectic and non-anorectic pancreatic islet tumors and 
in the normal islet of Langerhans. FEBS Lett. 1999 Mar 
26;447(2-3):139-43 
Kuhar MJ, Dall Vechia SE. CART peptides: novel 
addiction- and feeding-related neuropeptides. Trends 
Neurosci. 1999 Jul;22(7):316-20 
CARTPT (CART Prepropeptide) Landerholm K, Wierup N 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 456 
Kuhar MJ, Yoho LL. CART peptide analysis by Western 
blotting. Synapse. 1999 Sep 1;33(3):163-71 
Asnicar MA, Smith DP, Yang DD et al.. Absence of 
cocaine- and amphetamine-regulated transcript results in 
obesity in mice fed a high caloric diet. Endocrinology. 2001 
Oct;142(10):4394-400 
del Giudice EM, Santoro N, Cirillo G, D'Urso L, Di Toro R, 
Perrone L. Mutational screening of the CART gene in 
obese children: identifying a mutation (Leu34Phe) 
associated with reduced resting energy expenditure and 
cosegregating with obesity phenotype in a large family. 
Diabetes. 2001 Sep;50(9):2157-60 
Volkoff H, Peter RE. Characterization of two forms of 
cocaine- and amphetamine-regulated transcript (CART) 
peptide precursors in goldfish: molecular cloning and 
distribution, modulation of expression by nutritional status, 
and interactions with leptin. Endocrinology. 2001 
Dec;142(12):5076-88 
Ekblad E, Kuhar M, Wierup N, Sundler F. Cocaine- and 
amphetamine-regulated transcript: distribution and function 
in rat gastrointestinal tract. Neurogastroenterol Motil. 2003 
Oct;15(5):545-57 
Hunter RG, Philpot K, Vicentic A, Dominguez G, Hubert 
GW, Kuhar MJ. CART in feeding and obesity. Trends 
Endocrinol Metab. 2004 Nov;15(9):454-9 
Wierup N, Kuhar M, Nilsson BO, Mulder H, Ekblad E, 
Sundler F. Cocaine- and amphetamine-regulated transcript 
(CART) is expressed in several islet cell types during rat 
development. J Histochem Cytochem. 2004 
Feb;52(2):169-77 
Guérardel A, Barat-Houari M, Vasseur F et al.. Analysis of 
sequence variability in the CART gene in relation to 
obesity in a Caucasian population. BMC Genet. 2005 Apr 
11;6:19 
Wierup N, Richards WG, Bannon AW, Kuhar MJ, Ahrén B, 
Sundler F. CART knock out mice have impaired insulin 
secretion and glucose intolerance, altered beta cell 
morphology and increased body weight. Regul Pept. 2005 
Jul 15;129(1-3):203-11 
Dun SL, Brailoiu GC, Yang J, Chang JK, Dun NJ. Cocaine- 
and amphetamine-regulated transcript peptide and 
sympatho-adrenal axis. Peptides. 2006 Aug;27(8):1949-55 
Dylag T, Kotlinska J, Rafalski P, Pachuta A, Silberring J. 
The activity of CART peptide fragments. Peptides. 2006 
Aug;27(8):1926-33 
Ekblad E. CART in the enteric nervous system. Peptides. 
2006 Aug;27(8):2024-30 
Jaworski JN, Jones DC. The role of CART in the 
reward/reinforcing properties of psychostimulants. 
Peptides. 2006 Aug;27(8):1993-2004 
Stein J, Shah R, Steiner DF, Dey A. RNAi-mediated 
silencing of prohormone convertase (PC) 5/6 expression 
leads to impairment in processing of cocaine- and 
amphetamine-regulated transcript (CART) precursor. 
Biochem J. 2006a Nov 15;400(1):209-15 
Stein J, Steiner DF, Dey A. Processing of cocaine- and 
amphetamine-regulated transcript (CART) precursor 
proteins by prohormone convertases (PCs) and its 
implications. Peptides. 2006b Aug;27(8):1919-25 
Wierup N, Björkqvist M, Kuhar MJ, Mulder H, Sundler F. 
CART regulates islet hormone secretion and is expressed 
in the beta-cells of type 2 diabetic rats. Diabetes. 2006  
Feb;55(2):305-11 
Wierup N, Sundler F. CART is a novel islet regulatory 
peptide. Peptides. 2006 Aug;27(8):2031-6 
Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, 
Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, 
Scoazec JY, Wiedenmann B. TNM staging of midgut and 
hindgut (neuro) endocrine tumors: a consensus proposal 
including a grading system. Virchows Arch. 2007 
Oct;451(4):757-62 
Wierup N, Gunnarsdóttir A, Ekblad E, Sundler F. 
Characterisation of CART-containing neurons and cells in 
the porcine pancreas, gastro-intestinal tract, adrenal and 
thyroid glands. BMC Neurosci. 2007 Jul 11;8:51 
Bech P, Winstanley V, Murphy KG, Sam AH, Meeran K, 
Ghatei MA, Bloom SR. Elevated cocaine- and 
amphetamine-regulated transcript immunoreactivity in the 
circulation of patients with neuroendocrine malignancy. J 
Clin Endocrinol Metab. 2008 Apr;93(4):1246-53 
Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ. CART 
peptides: regulators of body weight, reward and other 
functions. Nat Rev Neurosci. 2008 Oct;9(10):747-58 
Sobin LH, Gospodarowicz MK, Wittekind C, editors.. UICC 
International Union Against Cancer: TNM Classification of 
Malignant Tumours (7th ed.). Wiley-Blackwell: Chichester, 
UK, 2009. 
Landerholm K, Falkmer SE, Jarhult J, Sundler F, Wierup 
N.. Cocaine- and amphetamine-regulated transcript in 
neuroendocrine tumors. Neuroendocrinology. 
2011;94(3):228-36. doi: 10.1159/000329044. Epub 2011 
Aug 11. 
Lin Y, Hall RA, Kuhar MJ.. CART peptide stimulation of G 
protein-mediated signaling in differentiated PC12 cells: 
identification of PACAP 6-38 as a CART receptor 
antagonist. Neuropeptides. 2011 Oct;45(5):351-8. doi: 
10.1016/j.npep.2011.07.006. Epub 2011 Aug 19. 
Brennan DJ, O'Connor DP, Laursen H et al.. The cocaine- 
and amphetamine-regulated transcript mediates ligand-
independent activation of ERα, and is an independent 
prognostic factor in node-negative breast cancer. 
Oncogene. 2012 Jul 26;31(30):3483-94. doi: 
10.1038/onc.2011.519. Epub 2011 Dec 5. 
Landerholm K, Shcherbina L, Falkmer SE, Jarhult J, 
Wierup N.. Expression of cocaine- and amphetamine-
regulated transcript is associated with worse survival in 
small bowel carcinoid tumors. Clin Cancer Res. 2012 Jul 
1;18(13):3668-76. doi: 10.1158/1078-0432.CCR-11-2513. 
Epub 2012 May 2. 
Sathanoori R, Olde B, Erlinge D, Goransson O, Wierup N.. 
Cocaine- and amphetamine-regulated transcript (CART) 
protects beta cells against glucotoxicity and increases cell 
proliferation. J Biol Chem. 2013 Feb 1;288(5):3208-18. doi: 
10.1074/jbc.M112.437145. Epub 2012 Dec 16. 
Bech PR, Martin NM, Ramachandran R, Bloom SR.. The 
biochemical utility of chromogranin A, chromogranin B and 
cocaine- and amphetamine-regulated transcript for 
neuroendocrine neoplasia. Ann Clin Biochem. 2014 
Jan;51(Pt 1):8-21. doi: 10.1177/0004563213489670. Epub 
2013 Aug 12. 
This article should be referenced as such: 
Landerholm K, Wierup N. CARTPT (CART Prepropeptide). 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7):453-
456. 
